Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks to all for the replies.
Don't get me wrong. I am, and have been for some time, long MARA. I was just highlighting whether or not the proposed legislation may scare investors.
MARA is the only "patent play" I currently hold as I believe it offers the best reward for the risk out of the bunch.
Yep, possibly a seller today was spooked by this news floating around:
http://mobile.reuters.com/article/idUSBRE9AK06620131121?feedType=RSS&irpc=932
I thought Stan Lee had millions $; you should be fine.
6 months.
Exactly. I was specifically looking for confirmation of the clinical trials moving forward and we got it! Fantastic news.
Looks like the only people fretting over the 10-Q are the usual bashers.
OTC market down. Should be back up at some point.
Yes, OTC down.
It's near the end of the presentation. I believe it's in a section about upcoming milestones.
I remember the volume being similar pre r/s. I think it may have been even worse pre r/s. MARA is still a relatively unknown, new company.
I started a position a few days ago. Feels like relatively low risk for a bio tech due to aldoxorubicin being a modification of doxorubicin. Plus, the recent offering reduces cash burn fears.
Agreed. Bought more sub .28
I.
I bought many shares from .25-.28. I'll buy more this week if ONCS dips below 0.30.
Yes! Which, hopefully, indicates the data/results look good.
This stock is back to where I first started watching it early this year. So much for that r/s!
Looks like a financial mess.
Have they actually produced something with their tamper resistant technology? If so, how long busboy stable. I'll pass.
I added shares sub .26 the past couple days. I'm new, but have been watching/reading the past two weeks and think this is a fantastic buy at these prices.
I just wanted someone to book my vacation and I thought their name sounded nice.
I started a position here early last week. Surprised there are no recent posts on I hub. This moved nicely Friday and I think that's just the start. Should be a nice month with the Master trial data coming up.
I think you are right. Dilution to raise more cash.
The question is how much more dilution will we see? We've gone through roughly 28 million shares in a week.
Fantastic post! Thank you.
I'm hoping it is accumulation now that word Is out that Frost is involved with BZNE.
Large trades after hours:
850k at .5654
25k at 0.59
650k at 0.56
http://www.nasdaq.com/symbol/bzne/after-hours
Any guesses as to a buyout price or value? All speculation of course, but curious to opinions.
Nice call, as usual, on HIPP.
I'm still holding most of the shares I purchased after your mention of HIPP. Today's pullback was expected.
Yep, and nothing you or I can do about it. Frustrating but common.
This offering is a temporary setback. Good in the long run.
Not very many is correct. Maybe 10-15 posters on this board are shareholders?
If MARA can get uplisted, we should/could see "smart," large institutional buyers move in. I would expect that to alleviate some of the share price grief that comes with trading on the OTC and bring greater exposure to new investors.
No brainer at 30 cents 2-3 weeks ago to now saying the value lies in the teens.
It's perfectly fine to change one's stance on a stock, but you definitely flip flop your opinion on WDDD often.
Unfortunately WDDD has turned into a financial mess. I can only wonder how things would be different if the Markman wasn't delayed earlier this summer.
Indeed. Fantastic recommendation!
I picked up an additional 10k shares late yesterday.
Someone was accumulating shares under $6 for the past week or so. Nice volume today. MARA should have no problem moving higher with good news.
Nice! Thanks for the heads up.
I've been trying to buy shares at 0.385 for the past week. No luck at that price.
I purchased 10k shares at .425 today as a starter.
Sure, he isn't pumping the stock in flashy fashion, but....
He provides some of the most beneficial posts for investors here, imo.
Nice post! Thanks for the write up.
Interesting AH action. It looks like HK is wanting to move up after today. Maybe a gap fill...
I never understood the SCRC love. I dont remember Tylenol meltaways ever being popular. Plus, the sublingual Viagra talk on ihub was overblown and it's already available outside the US from Pfizer (Viagra Jet).
I rode the first wave as essentially a swing trade thanks to the pumping. Those shares were bought at .18 which is close to where it sits today. I wouldn't feel comfortable buying it today at that price.
This stock is going to blow up at some point. It's just a matter of patience and riding out these dips. It's part of the game with a low float and minimal news with a patent play.
Any thoughts/feelings that someone is accumulating shares down here? I'm tempted to buy more myself in the current price range, but I don't like too throw too much of my portfolio in 1stock.
I still believe this is the best, and safest, patent play at this market cap range. Really that's a belief that has only gotten stronger the past couple months with watching (and trading most of these) DSS, BCYP, WDDD, VRNG, MGT, PRKR.
Very nice. Thanks for sharing!
Well, it's not bearish. It would be nice to see larger buys, BUT at least he's not selling and he is buying often. It has been difficult the past couple weeks to get my larger buys filled.
Thanks again for the recommendation.
I may look to start a small position after doing some reading/DD. I'll just watch for a good entry point.
Recent Intellectual Asset Management blurb/blog that focuses on HIPP:
http://bit.ly/19PM93u
For all shades of patent licensor, rebranding could reverse the anti-troll tide
Augme Technologies – which holds a number of patents relating to mobile marketing and advertising – last week changed its trade name to Hipcricket, a recognised brand it acquired in 2011. Augme’s rebrand appears to be aimed at increasing investor confidence and reducing negative perceptions of its patent monetisation activities; something that several leading NPEs are seeking to do with a number of different strategies.
It’s worth first taking the opportunity to have a look at Augme/Hipcricket’s activities. It is not clear how much, if any, of its business is currently accounted for by the development and sale of marketing services covered by its patents, as opposed to monetisation of the patents themselves. The company’s website states that:
Augme's platform has provided measurable successes across an industry-leading 250,000+ campaigns for its clients, which include many of America's brand-name leaders (e.g. MillerCoors, Clear Channel) in a variety of industries, along with their agencies. Augme's offerings allow marketers, brands, and agencies to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, MMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps[…] Augme also provides business-to-consumer solutions, including national mobile couponing campaigns, strategic mobile healthcare tools, custom mobile application development, and consumer data tracking and analytics.
What we can say for certain is that Augme/Hipcricket has initiated litigation several times to assert its patent rights. It is also worth noting that Don Stout is a director and board member at the company. Stout is a co-founder of NTP, the NPE which won a $612.5 million settlement payment for patent infringement from Research In Motion (now BlackBerry) in 2006.
In the ‘IP Markets’ column back in issue 58 of IAM, we examined the market valuations and patent holdings of the key publicly traded IP companies (PIPCOs). Augme – considered as a PIPCO in this instance – had one of the smallest IP portfolios of the companies listed, with seven patents at the time of publication. It would appear that this has expanded in the meantime thanks to a number of strategic acquisitions.
According to Patrick Anderson over at the Gametime IP blog, Augme (today’s Hipcricket) started life back in 1999 as Modavox, which developed, patented and marketed internet broadcast technology. In 2009, Modavox bought mobile marketing platform provider Augme Mobile, later adopting the acquisition’s name as its new corporate identity. In 2011, the company acquired QR code start-up Jagtag for $5.5 million and mobile advertising firm Hipcricket for $44.5 million.
Regardless of what proportion of Augme’s income is derived from patent licensing and how much from its operating business, what is important is that each revenue source supports and complements the other. “Companies in emerging industries enhance their ability to compete by incorporating a value-generating IP strategy,” Stout told Gametime IP. “Quality patents, strategically deployed, support young operating businesses and provide investors additional ways to achieve return.”
This goes the other way, too; companies that are focused on patent assertion and licensing would not have successful businesses if their intellectual property had no relevance to the product and service markets. In the most recent issue of IAM we looked at some of the ways in which patent monetisation companies are trying to expand and diversify their businesses. Acacia has made a number of significant strategic acquisitions of patents in a range of different technological areas, including oil and gas production, automotive and healthcare, taking its holdings beyond the telecommunications and computing fields which have until now provided NPEs with their bread and butter. It appears a similar strategy is also being pursued by CopyTele (which notably counts a number of former Acacia executives among its team). Others – including Rambus and Vringo – have looked to make a move into product and prototype development by actually practising on some of the patents they own.
Such strategies are designed to make the NPE business model better equipped for economic uncertainty and to sustain investor interest by opening additional value streams. But another factor that undoubtedly comes into play here is the potential toll of anti-patent sentiment, and the possibility of legislative reforms that could have a fundamental impact on the patent marketplace and the value of patent assets.
By launching own-branded products, Rambus paints itself as more than a patent monetisation entity – even if licensing continues to be its main source of revenue for some time to come. Likewise, Vringo’s toying with the idea of becoming more involved in product development shifts its perception in the eyes of IP sceptics from that of a ‘troll’ that “doesn’t actually produce anything themselves” (to paraphrase Barack Obama) to that of an ‘innovator’ making an easily comprehensible contribution to the economy. Perhaps by changing its name to Hipcricket – a brand which already enjoys consumer recognition and a decent reputation in its marketplace – Augme can deflect any potential controversy or negative attention that its patent monetisation activities might attract.